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Why use an allergy-based quality of life measure in childhood atopic 
eczema? 
 
Atopic dermatitis (AD) does not exist in an isolated dermatological vacuum. 
Many patients have other allergic diseases as they march through their atopic 
destiny: for example, 60% of children with severe AD may develop asthma1.  
The summed impact of these co-existing conditions is what is of relevance to 
the patient (and their family), not the skin effects alone.  To ensure a holistic 
assessment of our AD patients, should we use a broad-based questionnaire? 
 
The Paediatric Allergic Disease Quality of Life Questionnaire (PADQLQ) items 
were based on interviews with children with allergic asthma, rhino-
conjunctivitis and/or eczema2. Its questions range over effects on the eyes, ears, 
nose, lungs, emotions and everyday activities, and also the skin. Validation was 
undertaken in children with systemic manifestations of grass pollen allergy, 
seasonal allergic rhino-conjunctivitis, asthma and/or eczema.  And all subjects 
had to have symptoms that developed during the pollen season and positive 
results for a skin prick test to grass pollens.  Of the 25 questions, only 14 seem 
to be relevant to many children with atopic eczema. Remarkably, in view of 
these restricted origins, Hon et al in this issue3 have demonstrated good 
validation characteristics of PADQLQ in their AD patients. 
 
As might be expected, PADQLQ correlated better with another quality of life 
(QoL) measure, the Children’s Dermatology Life Quality Index (CDLQI)4, than 
with the symptom/sign measures Patient Oriented Eczema Measure (POEM) 
and Nottingham Eczema Severity Score (NESS).  One issue, important for 
many children, is that in contrast with CDLQI, PADQLQ does not contain 
items on bullying5.  However, it is reassuring that the PADQLQ scores in the 
domains “practical”, “emotional” and “symptoms” were greater in the severe 
AD patients than in “mild-moderate” AD patients3. 
 
Ways to measure dermatology-specific health-related QoL have mushroomed 
dramatically6 since the first childhood specific measure in 19954.  The major 
secondary burden of skin disease on families can now also be assessed7.  
Although Razny suggested that there are already too many QoL measures 
available for use in AD8, PADQLQ does contribute a new specific perspective, 
as it extends the usual classification of QoL measures.  It is neither a generic (all 
diseases) measure, disease specific, nor a specialty specific measure. Rather it is 
a “cross-over” measure, covering allergic diseases.  Perhaps one could envisage 
other hypothetical cross-over measures such as for “autoimmune disease”, or 
“drug reactions”. 
 
But what of practical issues in using PADQLQ?  According to Hon et al3 
completion of the 25 questions takes “less than ten minutes”, compared to two 
minutes to complete the 10 question CDLQI9, an important consideration if a 
QoL measure is to be used in routine busy clinical practice.  Although score
description bandings are available to give meaning to CDLQI scores, they do 
not exist for PADQLQ scores, limiting its clinical usefulness. 
 
Why is this relevant to dermatologists who look after children with AD?  The
management of such children should consider their co-existing conditions, and 
some therapies may benefit more than one atopic condition.  Some clinicians 
may not be aware of the extent of the combined impact of co-existing allergic 
disease on their patients. 
 
Hon et al3 have demonstrated “reasonably good agreement” between PADQLQ 
and CDLQI, begging the question as to why another measure may be helpful.  
However, their work on PADQLQ encourages us to view AD within a wider 
perspective and the measure may be useful in clinical research. But its value in 
routine dermatology practice remains at present untested. 
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